The reported statements, read against the company's own industry.
Financials view
Market Capitalization
485.50MEUR
539.78M · vs all stocks (USD)
Updated Oct 29, 2026
Revenue (TTM)
142.94MEUR
158.92M · vs all stocks (USD)
Updated Oct 29, 2026
Profit Margin
-110.29%
vs Biotechnology peers
Updated Oct 29, 2026
Beta
1.26x
vs all stocks
Updated Oct 29, 2026
52-Week Change
-36.42%
vs all stocks
Updated Oct 29, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 29, 2026
Market Capitalization
485.50MEUR
539.78M · vs all stocks (USD)
Updated Oct 29, 2026
Enterprise Value
558.46MEUR
620.91M · vs all stocks (USD)
Updated Oct 29, 2026
Forward P/E
16.08x
vs Biotechnology peers
Updated Oct 29, 2026
Price to Sales (TTM)
3.29x
vs Biotechnology peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 3.4×.Updated Oct 29, 2026
Price to Book (MRQ)
5.79x
vs Biotechnology peers
Updated Oct 29, 2026
Enterprise to Revenue
3.91x
vs Biotechnology peers
Updated Oct 29, 2026
Enterprise to EBITDA
-5.66x
vs Biotechnology peers
Updated Oct 29, 2026
Gross Margin
4.58%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives -41.73%.Updated Oct 29, 2026
Profit Margin
-110.29%
vs Biotechnology peers
Updated Oct 29, 2026
Operating Margin
-74.92%
vs Biotechnology peers
Updated Oct 29, 2026
Return on Assets (TTM)
-16.68%
vs Biotechnology peers
Updated Oct 29, 2026
Return on Equity (TTM)
-117.85%
vs Biotechnology peers
Updated Oct 29, 2026
Revenue (TTM)
142.94MEUR
158.92M · vs all stocks (USD)
Updated Oct 29, 2026
Revenue per Share (TTM)
0.8010EURUpdated Oct 29, 2026
Quarterly Revenue Growth
-27.70%
vs Biotechnology peers
Updated Oct 29, 2026
Gross Profit (TTM)
-59.65MEUR
-66.32M · vs all stocks (USD)
Updated Oct 29, 2026
EBITDA (TTM)
-98.72MEUR
-109.76M · vs all stocks (USD)
Updated Oct 29, 2026
Net Income (TTM)
-157.65MEUR
-175.28M · vs all stocks (USD)
Updated Oct 29, 2026
Quarterly Earnings Growth (YoY)
-27.71%
vs Biotechnology peers
Updated Oct 29, 2026
Operating Cash Flow (TTM)
-55.69MEUR
-61.92M · vs all stocks (USD)
Updated Oct 29, 2026
Levered Free Cash Flow (TTM)
-42.50MEUR
-47.25M · vs all stocks (USD)
Updated Oct 29, 2026
Forward Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 29, 2026
Trailing Annual Dividend Rate
0.00EURUpdated Oct 29, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Oct 29, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Updated Oct 29, 2026
Revenue
174.66MEURFY2025 · Dec 31, 2025
Cost of Goods Sold
107.14MEURFY2025 · Dec 31, 2025
Gross Profit
67.52MEURFY2025 · Dec 31, 2025
Operating Income
-81.63MEUR
-90.76M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-114.12MEURFY2025 · Dec 31, 2025
Income Tax Expense
1.07MEURFY2025 · Dec 31, 2025
Net Income
-115.19MEURFY2025 · Dec 31, 2025
EBIT
-72.22MEURFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-57.24MEURFY2025 · Dec 31, 2025
Research & Development
85.30MEURFY2025 · Dec 31, 2025
Selling, General & Administrative
74.68MEURFY2025 · Dec 31, 2025
Other Operating Expenses
-11.20MEURFY2025 · Dec 31, 2025
Non-operating Interest Income
1.80MEURFY2025 · Dec 31, 2025
Non-operating Interest Expense
41.90MEURFY2025 · Dec 31, 2025
EPS (Basic)
-0.6800EURFY2025 · Dec 31, 2025
EPS (Diluted)
-0.6800EURFY2025 · Dec 31, 2025
Basic Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-115.19MEURFY2025 · Dec 31, 2025
Operating Cash Flow
-48.13MEURFY2025 · Dec 31, 2025
Free Cash Flow
-52.42MEURFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
109.65MEURFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-115.19MEURFY2025 · Dec 31, 2025
Depreciation & Amortization
21.75MEURFY2025 · Dec 31, 2025
Deferred Taxes (CF)
1.07MEURFY2025 · Dec 31, 2025
Stock-based Compensation
9.53MEURFY2025 · Dec 31, 2025
Other Non-cash Items
30.40MEURFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
13.33MEURFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-9.02MEURFY2025 · Dec 31, 2025
Capital Expenditures
-4.29MEURFY2025 · Dec 31, 2025
Net Intangibles (CF)
-61.00KEURFY2025 · Dec 31, 2025
Net Acquisitions
0.00EURFY2025 · Dec 31, 2025
Sale of Investments
841.00KEURFY2025 · Dec 31, 2025
Net Investing Cash Flow
-3.45MEURFY2025 · Dec 31, 2025
Long-term Debt Issuance
174.40MEURFY2025 · Dec 31, 2025
Long-term Debt Payments
-174.34MEURFY2025 · Dec 31, 2025
Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025
Other Financing Charges
1.00KEURFY2025 · Dec 31, 2025
Net Financing Cash Flow
62.00KEURFY2025 · Dec 31, 2025
Shares Outstanding
204.24MSharesUpdated Oct 29, 2026
Float Shares
171.36MSharesUpdated Oct 29, 2026
% Held by Insiders
10.69%
vs all stocks
Updated Oct 29, 2026
% Held by Institutions
22.47%
vs all stocks
Updated Oct 29, 2026
Total Cash (MRQ)
121.53MEUR
135.12M · vs all stocks (USD)
Updated Oct 29, 2026
Total Cash per Share (MRQ)
0.6410EURUpdated Oct 29, 2026
Total Debt (MRQ)
210.23MEUR
233.74M · vs all stocks (USD)
Updated Oct 29, 2026
Total Debt to Equity (MRQ)
2.59x
vs Biotechnology peers
Updated Oct 29, 2026
Current Ratio (MRQ)
2.16x
vs Biotechnology peers
Updated Oct 29, 2026
Book Value per Share (MRQ)
0.4280EURUpdated Oct 29, 2026
Total Assets
398.84MEUR
443.43M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
222.54MEURFY2025 · Dec 31, 2025
Total Liabilities
292.67MEURFY2025 · Dec 31, 2025
Total Non-current Assets
176.30MEURFY2025 · Dec 31, 2025
Total Non-current Liabilities
199.33MEURFY2025 · Dec 31, 2025
Total Current Liabilities
93.33MEURFY2025 · Dec 31, 2025
Cash
109.65MEURFY2025 · Dec 31, 2025
Cash & Cash Equivalents
109.65MEURFY2025 · Dec 31, 2025
Accounts Receivable
27.73MEURFY2025 · Dec 31, 2025
Inventory
50.23MEURFY2025 · Dec 31, 2025
Accounts Payable
9.07MEURFY2025 · Dec 31, 2025
Short-term Debt
20.64MEURFY2025 · Dec 31, 2025
Deferred Revenue
432.00KEURFY2025 · Dec 31, 2025
Other Current Liabilities
5.69MEURFY2025 · Dec 31, 2025
Long-term Debt
186.60MEURFY2025 · Dec 31, 2025
Other Non-current Liabilities
245.00KEURFY2025 · Dec 31, 2025
Common Stock (Book)
26.03MEURFY2025 · Dec 31, 2025
Retained Earnings
-679.12MEURFY2025 · Dec 31, 2025
Total Shareholders' Equity
106.17MEUR
118.04M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
645.00KEURFY2025 · Dec 31, 2025
52-Week Low
2.03EURUpdated Oct 29, 2026
52-Week High
5.15EURUpdated Oct 29, 2026
52-Week Change
-36.42%
vs all stocks
Updated Oct 29, 2026
Beta
1.26x
vs all stocks
Updated Oct 29, 2026
50-Day MA
2.73EURUpdated Oct 29, 2026
200-Day MA
2.95EURUpdated Oct 29, 2026
Avg 10-Day Volume
413.10KSharesUpdated Oct 29, 2026
Avg 30-Day Volume
365.37KSharesUpdated Oct 29, 2026
Diluted EPS (TTM)
-0.9000EURUpdated Oct 29, 2026
Other Income / Expense
6.76MEURFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 4.6%, lower than 95% of its Biotechnology peers (median 65.4%)Significant